# Evofem Biosciences, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Evofem Biosciences, Inc.). ## Overview Evofem Biosciences, Inc. is a U.S.-based pharmaceutical company focused on commercializing women’s health products. Its core business centers on PHEXXI for pregnancy prevention and SOLOSEC for bacterial vaginosis and trichomoniasis, supported by telehealth and third-party commercialization channels. ## Products & services • PHEXXI prescription contraceptive gel • SOLOSEC for bacterial vaginosis and trichomoniasis • PHEXXI telehealth platform • Prescription product marketing and commercialization services - **Women’s health pharmaceuticals** (85%) — Prescription products used for pregnancy prevention and treatment of women’s health infections. - **Telehealth-enabled access** (10%) — Digital and remote channels used to support patient access and prescribing for PHEXXI. - **Commercialization and promotion** (5%) — Sales, marketing, and distribution activities supporting approved products. - PHEXXI prescription contraceptive gel - SOLOSEC for bacterial vaginosis and trichomoniasis - PHEXXI telehealth platform - Prescription product marketing and commercialization services ## Customers Evofem sells primarily into the prescription healthcare market, where the end users are patients and the economic buyers are typically payers, distributors, pharmacies, and healthcare providers. Its products are prescribed by physicians and other clinicians, with telehealth and specialty pharmacy channels helping reach women seeking contraception or treatment for BV and trichomoniasis. - **Women seeking contraception** (primary) — Patients and prescribers using PHEXXI for pregnancy prevention, often valuing a non-hormonal option. - **Women treated for BV and trichomoniasis** (primary) — Patients prescribed SOLOSEC for bacterial vaginosis and trichomoniasis treatment. - **Physicians and telehealth prescribers** (primary) — Clinicians who write prescriptions and determine whether the products are adopted in practice. - **Pharmacies and distributors** (secondary) — Channel partners that stock, dispense, and distribute the products to end users. - **Payers and reimbursement gatekeepers** (secondary) — Insurers and benefit managers that affect patient affordability and product uptake. - Women seeking non-hormonal pregnancy prevention - Patients treated for bacterial vaginosis or trichomoniasis - Physicians and clinicians who prescribe the products - Wholesalers, specialty pharmacies, and distributors - Payers and health systems that influence access and reimbursement ## Geography The company is headquartered in the United States and the available disclosures point to a primarily U.S.-centric commercial model. Geography matters mainly through U.S. regulatory oversight, telehealth rules, reimbursement access, and the domestic physician/pharmacy distribution network rather than through a broad international footprint. - Headquartered in the United States - Commercial activity appears concentrated in the U.S. prescription market - U.S. FDA regulation is central to product labeling and promotion - Telehealth strategy depends on state-level rules and reimbursement - Supply chain and third-party manufacturing risk are global, not local ## Strategy Evofem’s strategy is to keep PHEXXI and SOLOSEC commercially viable through direct marketing, telehealth access, and third-party commercialization support. The company is also focused on maintaining regulatory compliance and preserving access to contract manufacturing, distribution, and promotional partners that it does not fully control internally. - **Commercialize PHEXXI more effectively** (short-term) — PHEXXI is a core growth driver and depends on physician and patient acceptance. - **Sustain SOLOSEC sales and market access** (short-term) — SOLOSEC provides an additional approved product and diversifies the women’s health portfolio. - **Reduce dependence on third parties** (medium-term) — Manufacturing, distribution, and telehealth are outsourced and create execution risk. - Drive adoption of PHEXXI through telehealth and direct promotion - Support SOLOSEC commercialization in women’s health infections - Use third parties for manufacturing, distribution, and telehealth delivery - Maintain FDA-compliant labeling and promotion to protect market access - Build physician and patient awareness to improve product acceptance ## Risks Evofem is highly exposed to commercialization risk because its revenue depends on whether PHEXXI and SOLOSEC gain and retain market acceptance. It also faces meaningful regulatory, supply chain, and financing risk because it relies on third parties for manufacturing, distribution, and telehealth delivery while operating in a heavily regulated pharmaceutical market. - **Commercial acceptance of PHEXXI** [high] — Revenue depends heavily on whether physicians and patients adopt the product over competing contraceptive options. - **Dependence on third-party manufacturing and distribution** [high] — The company relies on two contract manufacturers and has limited internal distribution capability. - **FDA and promotion compliance** [high] — Prescription products are subject to strict rules on labeling and off-label promotion. - **Telehealth execution risk** [medium] — The PHEXXI telehealth platform depends on third parties, provider participation, and favorable state rules. - **Product liability and post-marketing claims** [medium] — Approved healthcare products can still face lawsuits, adverse events, or market setbacks after launch. - PHEXXI adoption may remain limited if physicians or patients prefer alternatives - SOLOSEC and PHEXXI depend on FDA-approved labeling and compliant promotion - Third-party manufacturers and suppliers create supply continuity risk - Telehealth access depends on privacy, reimbursement, and state regulation - Product liability and post-marketing compliance can create legal exposure ## Accounting The most important accounting judgment is revenue recognition, especially estimating variable consideration such as chargebacks, rebates, and patient support programs. The company also uses fair value accounting for certain financial instruments and must assess debt-related valuation changes, while ongoing estimates and contingencies can materially affect reported results and liquidity. - **Variable consideration reserves** — Can materially change reported net sales and gross-to-net deductions - **Fair value of financial instruments** — Can create volatility in other income/expense and reported earnings - **Revenue recognition and trade receivables** — Affects timing of revenue and allowance/reserve levels - **Contingencies and indemnifications** — May affect liabilities and cash flow if claims are triggered - Revenue is recorded net of chargebacks, rebates, and patient support estimates - Variable consideration reserves can materially change reported product revenue - Fair value changes on debt and financial instruments affect other income/expense - Stock-based compensation and professional fees affect operating expense trends - Contingent liabilities and indemnifications can create future expense risk --- *Last updated: 2026-04-28T20:05:40.027698+00:00*